Search Result
Results for "
SARS-CoV-2-IN-1
" in MedChemExpress (MCE) Product Catalog:
1
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-126085
-
(±)-L-AlliIN
|
SARS-CoV
|
Infection
|
(±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro) .
|
-
-
- HY-145592
-
RO7020531; RG7854
|
Toll-like Receptor (TLR)
|
Infection
|
Ruzotolimod is an orally active TLR7 agonist. Ruzotolimod is an immunomodulatory agent that can be used to study HBV, COVID-19, or SARS-CoV-2 infection .
|
-
-
- HY-135860
-
|
Virus Protease
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively .
|
-
-
- HY-161114
-
|
SARS-CoV
|
Infection
|
MDOLL-0229 (compound 27) is an antiviral agent that targets SARS-CoV-2 Mac1 and repress coronavirus replication. MDOLL-0229 inhibits SARS-CoV-2 Mac1 with an IC50 of 2.1 µM .
|
-
-
- HY-151113
-
|
SARS-CoV
|
Infection
|
ZINC000104379474 is a compound that targets SARS-CoV-2 endoribonuclease .
|
-
-
- HY-170399
-
|
SARS-CoV
Virus Protease
|
Infection
Cancer
|
SARS-CoV-2 PLpro-IN-1 (Compound 85) is a non-covalent and competitive inhibitor of SARS-CoV-2 PLpro with an IC50 of 15.06 μM and a Ki of 22.93 μM. SARS-CoV-2 PLpro-IN-1 inhibits the proliferation of Vero cell with an IC50 of 7.47 μM .
|
-
-
- HY-N10604
-
-
-
- HY-169200
-
|
SARS-CoV
|
Cancer
|
SARS-CoV-2 Mpro-IN-26 (compund 13) is a covalent inhibitor of SARS-CoV-2 Mpro .
|
-
-
- HY-155057
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-8 (compound 6b) is an antiviral agent with anti-SARS-CoV-2 properties .
|
-
-
- HY-163912
-
|
SARS-CoV
|
Infection
|
JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of SARS-CoV-2 infection .
|
-
-
- HY-162598
-
|
SARS-CoV
|
Infection
|
CET-1 is an antiviral agent that inhibits SARS-CoV-2. CET-1 significantly prevents pseudovirus from entering ACE2 h cells .
|
-
-
- HY-160943A
-
|
SARS-CoV
|
Infection
|
F594-1001 (compound 6) hydrochloride is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC50s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 hydrochloride directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity .
|
-
-
- HY-160943
-
|
SARS-CoV
|
Infection
|
F594-1001 (compound 6) is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC50s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity .
|
-
-
- HY-158905
-
MTDB-Alk
|
SARS-CoV
|
Infection
|
MTDB-Alkyne is an alkyne-containing click chemistry reagent. MTDB-Alkyne can be used to synthesize Proximity-Induced Nucleic Acid Degrader (PINAD) for the degradation of SARS-CoV-2 RNA .
|
-
-
- HY-153533
-
|
SARS-CoV
|
Infection
|
GRL-1720 is a potent SARS-CoV-2 Mpro inhibitor with an EC50 value of 15 µM. GRL-1720 shows anti-SARS-CoV2 activity .
|
-
-
- HY-126085R
-
|
SARS-CoV
|
Infection
|
(±)-Alliin (Standard) is the analytical standard of (±)-Alliin. This product is intended for research and analytical applications. (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro) .
|
-
-
- HY-139165
-
|
SARS-CoV
|
Infection
|
AT-9010, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 can inhibit SARS-CoV-2 replication .
|
-
-
- HY-144464
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent, selective and irreversible inhibitor of SARS-CoV-2 main protease (Mpro), with an IC50 of 116 nM .
|
-
-
- HY-153533A
-
|
SARS-CoV
|
Infection
|
GRL-1720 TFA is a potent inhibitor of SARS-CoV-2 Mpro with an EC50 value of 15 μM. GRL-1720 TFA shows anti-SARS-CoV2 activity .
|
-
-
- HY-139165B
-
|
SARS-CoV
|
Infection
|
AT-9010 triethylamine, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 triethylamine can inhibit SARS-CoV-2 replication .
|
-
-
- HY-139165A
-
|
SARS-CoV
|
Infection
|
AT-9010 tetrasodium, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 tetrasodium can inhibit SARS-CoV-2 replication .
|
-
-
- HY-145994
-
ATV006
|
SARS-CoV
|
Infection
|
Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research .
|
-
-
- HY-155813
-
|
SARS-CoV
|
Infection
|
MPI60 is a potent SARS-CoV-2 M Pro inhibitor with high antiviral potency, low cellular cytotoxicity, and high in vitro metabolic stability. MPI60 can be used for SARS-CoV-2 research .
|
-
-
- HY-P9801
-
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody
|
SARS-CoV
|
Infection
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
-
- HY-P99435
-
BRII-196
|
SARS-CoV
|
Infection
|
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
|
-
-
- HY-170545
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-35 (compound 14) is a SARS-CoV-2 Mpro inhibitor. SARS-CoV-2 Mpro-IN-35 can be used for the research of SARS-CoV-2 virus .
|
-
-
- HY-P5168S
-
|
Isotope-Labeled Compounds
|
Infection
|
GPSVFPLAPSSK- 13C6 is the 13C labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .
|
-
-
- HY-146998
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .
|
-
-
- HY-112894
-
|
JNK
SARS-CoV
|
Inflammation/Immunology
|
ZG-10 (JNK-IN-2) is a JNK inhibitor, with IC50 values of 809 nM, 1140 nM and 709 nM for JNK1, JNK2, and JNK3, respectively. ZG-10 (JNK-IN-2) is a potential anti-SARS-CoV-2 agent .
|
-
-
- HY-157477
-
|
SARS-CoV
Cathepsin
|
Infection
|
SARS-CoV-2 3CLpro-IN-22 (Compound 17) is a cathepsin L (CTSL ) inhibitor with an IC50 value of 32.5 nM. SARS-CoV-2 3CLpro-IN-22 can be used for the study of SARS-CoV-2 virus .
|
-
-
- HY-158687
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 Mpro-IN-18 (compound 84) is a potent SARS-CoV-2 Mpro inhibitor with the IC50 of 3.23 nM. SARS-CoV-2 Mpro-IN-18 can be used for study of anti-SARS-CoV-2 agent .
|
-
-
- HY-155654
-
|
SARS-CoV
Virus Protease
|
Infection
|
SARS-CoV-2 Mpro-IN-10 (27h) is a potent M pro inhibitor with IC50 value and EC50 values of 10.9 nM and 43.6 nM, respectively. SARS-CoV-2 Mpro-IN-10 can be used for the research of SARS-CoV-2 virus .
|
-
-
- HY-162550
-
|
SARS-CoV
|
Infection
|
Jobosic acid, a saturated fatty acid, is a selective SARS-CoV-2 inhibitor. Jobosic acid inhibits Mpro and spike-RBD/ACE-2 interaction with IC50 values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid shows viral entry inhibition for the omicron SARS-CoV-2 variant .
|
-
-
- HY-P99604
-
AZD-1061; CoV2-2130
|
SARS-CoV
|
Infection
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
-
-
- HY-149304
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC50s of 100 nM and 160 nM respectively .
|
-
-
- HY-150784
-
|
SARS-CoV
|
Infection
|
XR8-89 is a potent papain-like protease (PL pro) inhibitor with an IC50 value of 0.1 μM. XR8-89 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. XR8-89 can be used for SARS-CoV-2 research .
|
-
-
- HY-150786
-
|
SARS-CoV
|
Infection
|
PLP_Snyder530 is a potent papain-like protease (PL pro) inhibitor with an IC50 value of 6.4 μM. PLP_Snyder530 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. PLP_Snyder530 can be used for SARS-CoV-2 research .
|
-
-
- HY-169171
-
|
Cathepsin
|
Infection
|
Cathepsin L-IN-5 (D6-3) is a potent Cathepsin L (CatL) inhibitor with an IC50 of 0.27 nM. Cathepsin L-IN-5 effectively blocks the CatL function and substantially hinders the entry of the SARS-CoV-2 pseudovirus to cells by inhibiting the cleavage of the spike protein. Cathepsin L-IN-5 can be utilized in SARS-CoV-2 research .
|
-
-
- HY-124304
-
LOE-908
|
TRP Channel
SARS-CoV
|
Neurological Disease
|
Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity .
|
-
-
- HY-150783
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-24 (compound 7) is a potent papain-like protease (PL pro) inhibitor. SARS-CoV-2-IN-24 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. SARS-CoV-2-IN-24 can be used for SARS-CoV-2 research .
|
-
-
- HY-P3626
-
SPL7013 free base
|
Bacterial
HCV
SARS-CoV
|
Infection
|
Astodrimer (SPL7013 free base) is a large (3-4 nm, ~ 16.5 kDa), negatively charged, highly-branched dendrimer, is a potent virucidal agent. Astodrimer shows antiviral and virucidal activity against a broad spectrum of viruses, including SARS-CoV-2, HIV-1, HSV-1, HSV-2, HPV. Astodrimer also has antibacterial properties .
|
-
-
- HY-155488
-
ATV014
|
SARS-CoV
|
Infection
|
SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of
coronavirus disease 2019 (COVID-19) .
|
-
-
- HY-P99340
-
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
-
-
- HY-163029
-
|
Cathepsin
SARS-CoV
|
Infection
|
CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC50s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research .
|
-
-
- HY-155416
-
|
SARS-CoV
|
Infection
|
M56-S2 iodide is a SARS-CoV-2 M pro inhibitor (IC50=4.0 μM). M56-S2 iodide showed good oral bioavailability and low toxicity in ADMET prediction. M56-S2 iodide has good drug potential and can be used in antiviral (such as SARS-CoV-2) research .
|
-
-
- HY-162507
-
|
Biochemical Assay Reagents
|
Infection
|
2'-RIBOTAC-U recruiter-linker (Compound 9) consists of RNase L recruiter and linker. 2'-RIBOTAC-U recruiter-linker is reacted separately with 2’-azido-uridine or 5’-azidomethyl-uridine via copper-catalyzed click chemistry, resulting in the formation of 2’-RIBOTAC-U and 5’-RIBOTAC-U, respectively. 2’-RIBOTAC-U has anti-SARS-CoV-2 activity .
|
-
-
- HY-131603
-
3TCTP
|
Reverse Transcriptase
HCV
HBV
SARS-CoV
|
Infection
|
Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the Reverse Transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .
|
-
-
- HY-117626
-
|
AAK1
Cyclin G-associated Kinase (GAK)
SARS-CoV
|
Infection
Neurological Disease
Inflammation/Immunology
|
LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research .
|
-
-
- HY-150062
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor with the IC50 value of 6.1 μM. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity. SARS-CoV-2 nsp3-IN-1 demonstrates notable selectivity for coronavirus macrodomains, especially towards SARS-CoV-2 Mac1 .
|
-
-
- HY-155983
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp14-IN-4 (Compound 12q) is a selective SARS-CoV-2 nsp14 methyltransferase inhibitor with an IC50 value of 19 ± 2.5 nM. SARS-CoV-2 nsp14-IN-4 (Compound 12q) do not have a zwitterionic character and can penetrate into cells. SARS-CoV-2 nsp14-IN-4 (Compound 12q) can be used for COVID-19 and its causative agent SARS-CoV-2 research .
|
-
- HY-161261
-
|
AAK1
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-81 (compound 12e) is a potent AAK1 inhibitor with an IC50 value of 9.38 nM. SARS-CoV-2-IN-81 shows anti-viral property against SARS-CoV-2. SARS-CoV-2-IN-81 attenuates AAK1-induced phosphorylation of AP2M1 threonine 156 and disrupts the direct interaction between AP2M1 and ACE2, ultimately inhibiting SARS-CoV-2 infection .
|
-
- HY-162484
-
|
SARS-CoV
Virus Protease
|
Infection
|
GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL pro), with an IC50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration Cmax of 549 ng/mL, a half-life T1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3626
-
SPL7013 free base
|
Bacterial
HCV
SARS-CoV
|
Infection
|
Astodrimer (SPL7013 free base) is a large (3-4 nm, ~ 16.5 kDa), negatively charged, highly-branched dendrimer, is a potent virucidal agent. Astodrimer shows antiviral and virucidal activity against a broad spectrum of viruses, including SARS-CoV-2, HIV-1, HSV-1, HSV-2, HPV. Astodrimer also has antibacterial properties .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9801
-
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody
|
SARS-CoV
|
Infection
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
- HY-P99435
-
BRII-196
|
SARS-CoV
|
Infection
|
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
|
-
- HY-P99604
-
AZD-1061; CoV2-2130
|
SARS-CoV
|
Infection
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
-
- HY-P99340
-
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-P5168S
-
|
GPSVFPLAPSSK- 13C6 is the 13C labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-158905
-
MTDB-Alk
|
|
Alkynes
|
MTDB-Alkyne is an alkyne-containing click chemistry reagent. MTDB-Alkyne can be used to synthesize Proximity-Induced Nucleic Acid Degrader (PINAD) for the degradation of SARS-CoV-2 RNA .
|
-
- HY-162507
-
|
|
Alkynes
|
2'-RIBOTAC-U recruiter-linker (Compound 9) consists of RNase L recruiter and linker. 2'-RIBOTAC-U recruiter-linker is reacted separately with 2’-azido-uridine or 5’-azidomethyl-uridine via copper-catalyzed click chemistry, resulting in the formation of 2’-RIBOTAC-U and 5’-RIBOTAC-U, respectively. 2’-RIBOTAC-U has anti-SARS-CoV-2 activity .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: